Evidence map›Paper›PMID 19995983›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2009

Target identification using drug affinity responsive target stability (DARTS).

Brett Lomenick, Rui Hao, Nao Jonai, Randall M Chin, Mariam Aghajan, Sarah Warburton, Jianing Wang, Raymond P Wu, Fernando Gomez, Joseph A Loo and 7 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 513 papers.

0numbers the graph read from it
0cells of the map it votes in
513citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

513 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Harmine Hydrochloride fromPharmaceuticals (Basel, Switzerland) · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Anisodus tanguticus in Cancer Research: A Review of Traditional Use, Phytochemistry, Extraction Methods, and Preclinical Antitumor Evidence.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  19. Article
  20. Review

453 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Brett LomenickDepartment of Molecular and Medical Pharmacology and the Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Rui Hao
Nao Jonai
Randall M Chin
Mariam Aghajan
Sarah Warburton
Jianing Wang
Raymond P Wu
Fernando Gomez
Joseph A Loo
James A Wohlschlegel
Thomas M Vondriska
Jerry Pelletier
Harvey R Herschman
Jon Clardy
Catherine F Clarke
Jing Huang

Funding

CHEMISTRY BIOLOGY INTERFACE TRAINING PROGRAMT32GM008496 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MAYNARD, HEATHER D · 1993 to 2019
$6.3M
Novel mechanisms of tyrosine kinase signaling in heartR01HL087132 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VONDRISKA, THOMAS M. · 2007 to 2011
$2.3M
Exploiting TOR Signaling for Cancer Drug DiscoveryR01CA124974 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HUANG, JING · 2007 to 2011
$1.5M
PURCHASE OF PROTEOMIC MASS SPECTROMETRY INSTRUMENTATION: CARDIOLOGYS10RR022371 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VONDRISKA, THOMAS MARTIN · 2006 to 2006
$498k
Phenotypic Continuum Between Cardiac Growth and ProtectionR21HL096041 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VONDRISKA, THOMAS M. · 2009 to 2010
$424k
A Novel Method for Identifying the Molecular Targets of Bioactive Food ComponentsR21CA149774 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HUANG, JING · 2010 to 2011
$363k
A Mixed-Bait-Strategy for Protein Interactome MappingR21HG003729 · NHGRI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HUANG, JING · 2006 to 2007
$280k
NCI NIH HHS R01 CA124974NCI NIH HHS R21 CA149774NCRR NIH HHS S10 RR022371NHGRI NIH HHS R21 HG003729NHLBI NIH HHS R01 HL087132NHLBI NIH HHS R21 HL096041NIGMS NIH HHS T32 GM008496
6 · The paper itself

Abstract

Identifying the molecular targets for the beneficial or detrimental effects of small-molecule drugs is an important and currently unmet challenge. We have developed a method, drug affinity responsive target stability (DARTS), which takes advantage of a reduction in the protease susceptibility of the target protein upon drug binding. DARTS is universally applicable because it requires no modification of the drug and is independent of the mechanism of drug action. We demonstrate use of DARTS to identify known small-molecule-protein interactions and to reveal the eukaryotic translation initiation machinery as a molecular target for the longevity-enhancing plant natural product resveratrol. We envisage that DARTS will also be useful in global mapping of protein-metabolite interaction networks and in label-free screening of unlimited varieties of compounds for development as molecular imaging agents.

Indexed as

Drug Delivery SystemsBinding SitesDNA, ComplementaryProteomicsResveratrolStilbenesDNA, ComplementaryResveratrolStilbenes

Identifiers

PMID19995983
PMCPMC2789755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.